Vnitr Lek 2020, 66(3):160-168 | DOI: 10.36290/vnl.2020.045

Long term antithrombotic threapy after myocardial infarction: why, to whom and which one?

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Despite the progress in secondary prevention, life expectancy after myocardial infarction is poor for some specific groups of patients. High ischemic risk patients could benefit from some strategies of long-term and aggressive antithrombotic therapy provided that their bleeding risk is acceptably low.

Keywords: antiplatelet therapy, anticoagulant therapy, acute myocardial infarction.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Long term antithrombotic threapy after myocardial infarction: why, to whom and which one? Vnitr Lek. 2020;66(3):160-168. doi: 10.36290/vnl.2020.045.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jernberg T, Hasvold P, Henriksson M. Cardiovascular risk in post‑myocardial infarction patients: nationwide real world data demonstrate the importance of a long‑term perspective. Eur Heart J 2015; 36: 1163-1170. Go to original source... Go to PubMed...
    2. Abtan J, Bhatt DL, Elbez Y. Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH registry. Clin Cardiol 2016; 39: 670-607. Go to original source... Go to PubMed...
    3. Varenhorst C, Hasvold P, Johansson S. Culprit and nonculprit recurrent ischemic events in patients with myocardial Infarction: Data from SWEDEHEART. J Am Heart Assoc 2018;7: e007174. DOI: 10.1161.JAHA.117.007174. Go to original source... Go to PubMed...
    4. Nakatani D, Sakata Y, Suna S. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2013; 77: 439-446. Go to original source... Go to PubMed...
    5. Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717. Go to original source... Go to PubMed...
    6. Bhatt DL, Flather MD, Hacke W. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8. Go to original source... Go to PubMed...
    7. Roe MT, Armstrong PW, Fox KA. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-1309. Go to original source... Go to PubMed...
    8. Bonaca MP, Bhatt DL, Cohen M. Long‑term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800. Go to original source... Go to PubMed...
    9. Bonaca MP, Bhatt DL, Steg PG. Ischaemic risk a efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS‑TIMI 54. Eur Heart J 2016; 37: 1133-1142. Go to original source... Go to PubMed...
    10. Dellborg M, Bonaca MP, Storey RF. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS‑TIMI 54. Eur Heart J 2017; 38(suppl): 794-795. Go to original source...
    11. Magnani G, Storey RF, Steg PG. Efficacy and safety of ticagrelor for long‑term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS‑TIMI 54 trial. Eur Heart J 2016; 37: 400-408. Go to original source...
    12. Bonaca MP, Bhatt DL, Storey RF. Ticagrelor in prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 719-728. Go to original source... Go to PubMed...
    13. Valgimigli M, Bueno H, Byrne RA. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213-254. Go to original source... Go to PubMed...
    14. Neumann FJ, Sousa‑Uva M, Ahlsson A. 2018 ESC.EACTS guidelines on myocardial revascularization. Eurointervention 2019; 14: 1435-1534. Go to original source... Go to PubMed...
    15. Hurlen M, Abdelnoor M, Smith P. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974. Go to original source... Go to PubMed...
    16. Rothberg MB, Celestin C, Fiore LD. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta‑analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250. Go to original source... Go to PubMed...
    17. Oldgren J, Budaj A, Granger CB. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double‑blind, phase II trial. Eur Heart J 2011; 32: 2781-2789. Go to original source... Go to PubMed...
    18. Alexander JH, Lopes RD, James S. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708. Go to original source... Go to PubMed...
    19. Mega JL, Braunwald E, Wiviott SD. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19. Go to original source... Go to PubMed...
    20. Connolly SJ, Eikelboom JW, Bosch J. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double‑blind, placebo‑controlled trial. Lancet 2018; 391: 205-218. Go to original source... Go to PubMed...
    21. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019; doi:10.1093.eurheartj.ehz425.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.